PR Newswire
LAS VEGAS, Feb. 24, 2026
DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment advances, aging demographics, increased awareness, and supportive regulations across the 7MM. Additionally, the launch of emerging drugs such as will further propel the market growth.
LAS VEGAS, Feb. 24, 2026 /PRNewswire/ — Recently published Drug-Resistant Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, drug-resistant epilepsy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Drug-Resistant Epilepsy Market Summary
- The total drug-resistant epilepsy treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounts for the largest market size of drug-resistant epilepsy, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
- 20-40% of epilepsy patients in the US are likely have refractory epilepsy. This significant prevalence underscores the need for advanced treatment options.
- Leading drug-resistant epilepsy companies, such as Neurona Therapeutics, IAMA Therapeutics, Bright Minds Bio, and others, are developing new drug-resistant epilepsy treatment drugs that can be available in the drug-resistant epilepsy market in the coming years.
- The promising drug-resistant epilepsy therapies in clinical trials include NRTX-1001, IAMA-6, BM-101, and others.
Discover what is the global market size for drug-resistant epilepsy and projected forecasts by year 2036 @ https://www.delveinsight.com/sample-request/drug-resistant-epilepsy-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Drug-Resistant Epilepsy Market
- Rising Prevalence of Epilepsy and Drug-Resistant Cases: Increasing global incidence of epilepsy, particularly in pediatric and elderly populations, expands the addressable patient pool. A substantial subset of epilepsy patients (~30%) do not respond adequately to first-line antiepileptic drugs (AEDs), driving demand for specialized therapies and interventions.
- Advancements in Therapeutic Approaches: Technologies like vagus nerve stimulation (VNS), responsive neurostimulation (RNS), deep brain stimulation (DBS), and emerging neuromodulation platforms are expanding treatment options.
- Launch of Emerging DRE Therapies: The dynamics of the drug-resistant epilepsy market are anticipated to change in the coming years due to the launch of emerging drugs and devices, including NRTX-1001 (Neurona Therapeutics), IAMA-6 (IAMA Therapeutics), BM-101 (Bright Minds Bio), and others.
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, commented that advancing the drug-resistant epilepsy pipeline reflects growing recognition of DRE as a biologically distinct, high-unmet-need condition and supports cautious optimism for durable, disease-modifying therapies and an increasingly differentiated epilepsy market.
Drug-Resistant Epilepsy Market Analysis
- The treatment paradigm for DRE, or more generally, its management strategies, comprises three main categories: pharmacotherapy, surgery, and alternative treatments, including neurostimulation, the ketogenic diet, and lifestyle changes.
- For about one in three people with epilepsy, medications are not sufficient, and seizures that persist despite two appropriate anti-seizure medications meet the definition of drug-resistant epilepsy.
- Vagus nerve stimulation (VNS) therapy, an FDA-approved neurostimulation modality, offers an alternative option when medications fail.
- Currently, no FDA-approved drugs exist specifically for DRE as a distinct condition, and available medications only target seizure reduction within defined seizure types or syndromes.
- Commonly used agents in refractory epilepsy, such as EPIDIOLEX, ZTALMY, XCOPRI, BANZEL, ONFI, and FYCOMPA, are utilized based on seizure phenotype rather than a DRE-specific indication.
- The therapeutic landscape is evolving, with investigational candidates such as NRTX-1001, IAMA-6, and BMB-101 exploring novel mechanisms, including network inhibition, synaptic excitability modulation, and biased receptor signaling.
Drug-Resistant Epilepsy Competitive Landscape
Some of the drug-resistant epilepsy therapies and devices in the pipeline include NRTX-1001 (Neurona Therapeutics), IAMA-6 (IAMA Therapeutics), BM-101 (Bright Minds Bio), and others.
Neurona Therapeutics’ NRTX-1001 is produced from human stem cells that are transformed into interneurons resembling those naturally present in the brain. These cells release GABA, a major neurotransmitter thought to reduce seizure activity by dampening overactive neural circuits.
IAMA Therapeutics’ IAMA-6 is an orally delivered small-molecule therapy designed to selectively block NKCC1 and help rebalance neuronal excitability. Increased NKCC1 activity is associated with several disease states, underscoring the therapeutic potential of targeting this transporter in drug-resistant epilepsy and other neurological conditions.
Bright Minds Bio’s BMB-101 is a first-in-class, structure-guided agonist of the 5-HT2C receptor that favors Gq-protein signaling. It is purposefully designed for chronic neurological diseases in which tolerance and treatment resistance limit long-term outcomes. By activating the Gq pathway while avoiding β-arrestin signaling, BMB-101 aims to minimize receptor desensitization and slow tolerance development. This pathway-selective approach within a well-validated receptor system supports a distinct anti-seizure mechanism intended to provide durable seizure control for patients with difficult-to-treat epilepsy.
The anticipated launch of these emerging therapies are poised to transform the drug-resistant epilepsy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the drug-resistant epilepsy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about what therapies are driving market growth for drug-resistant epilepsy @ Drug-Resistant Epilepsy Drugs Market
Recent Developments in the Drug-Resistant Epilepsy Market
- In January 2026, Bright Minds Biosciences reported positive Phase II BREAKTHROUGH trial results for BMB-101 in adults with drug-resistant absence seizures and developmental and epileptic encephalopathies, demonstrating up to a 73% median reduction in seizures, improved REM sleep, and favorable tolerability, with preparations underway for global registrational trials.
- In November 2025, Neurona Therapeutics announced that NRTX-1001 received EMA PRIME designation for the treatment of adults with drug-resistant focal epilepsy, supporting accelerated development and regulatory engagement in the EU.
- In April 2025, Neurona Therapeutics reported new results from its early-stage clinical trial of NRTX-1001, an experimental treatment for adults with drug-resistant mesial temporal lobe epilepsy (MTLE). The data was presented at this year’s American Academy of Neurology Annual Meeting in San Diego, offering a glimpse into potential progress for patients with limited treatment options.
- In April 2025, IAMA Therapeutics secured approximately 18 million USD in funding to advance its neuroscience pipeline, including lead candidate IAMA-6, which is currently being evaluated in a Phase I clinical trial (NCT06300398).
What is Drug-Resistant Epilepsy?
Drug-resistant epilepsy (DRE), also called refractory or intractable epilepsy, is a condition in which a person’s seizures continue despite trying at least two appropriately chosen and well-tolerated anti-seizure medications, either alone or in combination. In DRE, the brain’s abnormal electrical activity does not respond adequately to standard drug therapy, leading to ongoing seizures that can significantly affect daily life, safety, and overall health. Because medications are not sufficient, people with drug-resistant epilepsy often require specialized evaluation to explore other treatment options such as epilepsy surgery, neurostimulation devices, or dietary therapies.
Drug-Resistant Epilepsy Epidemiology Segmentation
The drug-resistant epilepsy epidemiology section provides insights into the historical and current drug-resistant epilepsy patient pool and forecasted trends for the leading markets. DRE tends to be more common in adults than in children. While around 7% to 20% of kids with epilepsy struggle to control their seizures with medication, that number jumps to between 30% and 40% in adults.
The drug-resistant epilepsy treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Age- specific Diagnosed Prevalent Cases of Epilepsy
- Treatable Cases of Epilepsy
- DRE Cases
Drug-Resistant Epilepsy Market Forecast Report Metrics
Details
Study Period
2022-2036
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and
Spain), the United Kingdom, and Japan].
Drug-Resistant Epilepsy Epidemiology Segmentation Age- specific Diagnosed Prevalent Cases of Epilepsy, Treatable
Cases of Epilepsy, and DRE Cases
Key Drug-Resistant Epilepsy Companies Neurona Therapeutics, IAMA Therapeutics, Bright Minds Bio, and
others
Key Drug-Resistant Epilepsy Therapies
NRTX-1001, IAMA-6, BM-101, and others
Scope of the
Drug-Resistant Epilepsy
Market Report
- Therapeutic Assessment: Drug-Resistant Epilepsy current marketed and emerging therapies
- Drug-Resistant Epilepsy Market Dynamics: Key Market Forecast Assumptions of Emerging Drug-Resistant Epilepsy Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Drug-Resistant Epilepsy Market Access and Reimbursement
Download the report to understand what are the unmet needs in treating drug-resistant epilepsy @ Drug-Resistant Epilepsy Market Forecast
Table of Contents
1 Drug-Resistant Epilepsy Market Key Insights
2 Drug-Resistant Epilepsy Market Report
Introduction
3
DRE Market Overview at a Glance
3.1 Market Share (%) Distribution of DRE by Therapies
in 2025
3.2 Market Share (%) Distribution of DRE by Therapies
in 2036
4
Executive Summary
5
Epidemiology and Market Methodology
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4 Potential Mechanisms of Anti-Seizure Drug (ASD)
Resistance
7.5
Classification
7.6
Risk Factors
7.7
Pathophysiology of Epilepsy
7.8
Diagnosis
7.9
Treatment
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.3
Total DRE Cases in the 7MM
8.4
United States
8.4.1 Age- specific Diagnosed Prevalent cases of
Epilepsy
8.4.2
Treatable Cases of Epilepsy
8.4.3
DRE Cases
8.5
EU4 and the UK
8.6
Japan
9 Drug-Resistant Epilepsy Patient Journey
10 Marketed Drug-Resistant Epilepsy Therapies
10.1
Key Cross Competition
10.2
VNS System: LivoNova
10.2.1
Product Description
10.2.2
Other Development Activities
10.2.3
Clinical Development
10.2.4
Clinical Trials Information
10.2.5
Safety and Efficacy
List to be continued in the report…
11 Emerging Drug-Resistant Epilepsy Therapies
11.1
Key Cross Competition
11.2
NRTX-1001: Neurona Therapeutics
11.2.1
Drug Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analysts’ View
11.3
IAMA-6: IAMA Therapeutics
11.4
BM-101: Bright Minds Bio
List to be continued in the report…
12 Drug-Resistant Epilepsy Market: 7MM Analysis
12.1
Key Findings
12.2 Key Drug-Resistant Epilepsy Market Forecast
Assumptions
12.3
Drug-Resistant Epilepsy Market Outlook
12.4
Attribute Analysis
12.5
Market Size of DRE in the 7MM
12.6 Total Market Size of DRE by Therapies in the 7MM
12.7 United States Drug-Resistant Epilepsy Market
Size
12.7.1
Total Market Size of DRE
12.7.2 Market size of DRE by Therapies in the US
12.8 EU4 and the UK Drug-Resistant Epilepsy Market
Size
12.9
Japan Drug-Resistant Epilepsy Market
13 Key Opinion Leaders’ Views on Drug-Resistant
Epilepsy
14 Drug-Resistant Epilepsy Market SWOT Analysis
15 Drug-Resistant Epilepsy Market Unmet Needs
16 Drug-Resistant Epilepsy Market Access and
Reimbursement
16.1
The United States
16.2
In EU4 and the UK
16.3
Japan
17
Bibliography
18
Acronyms and Abbreviations
19 Drug-Resistant Epilepsy Market Report
Methodology
Related Reports
Drug-Resistant Epilepsy Clinical Trial Analysis
Drug-Resistant Epilepsy Pipeline Insight
– 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Drug-Resistant Epilepsy companies, including ES Therapeutics, PTC Therapeutics, Aadi Bioscience, MGC Pharma, UCB, Zogenix, and others.
Epilepsy Market
Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies, including Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
Chronic Focal Epilepsy Market
Chronic Focal Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic focal epilepsy companies, including GlaxoSmithKline, Sanofi, UCB Pharma, Eisai, Medtronic, and others.
Partial Epilepsy Market
Partial Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key partial epilepsy companies, including Vertex Pharmaceuticals, Supernus Pharmaceuticals, Xenon Pharmaceuticals, UCB Pharmaceuticals, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/drug-resistant-epilepsy-market-to-accelerate-with-significant-cagr-by-2036-as-demand-for-advanced-therapies-increases–delveinsight-302695302.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…